Vaughn DJ, et al. - Researchers reported the results of health-related quality-of-life (HRQoL) analyses from the phase III KEYNOTE-045 trial, wherein pembrolizumab was shown to significantly prolong overall survival compared with investigator’s choice of chemotherapy in patients with previously treated advanced urothelial cancer. A prolonged time to deterioration (TTD) in HRQoL was provided by pembrolizumab vs chemotherapy. Stable or improved global health status/quality of life was seen with pembrolizumab treatment, whereas declines in global health status/quality of life were reported for patients treated with investigator’s choice of chemotherapy. Overall, pembrolizumab as standard of care for patients with platinum-refractory advanced urothelial cancer was supported.